CurrentUnitedHealthcarePolicy 2026T0589Z

Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions)

This policy reviews evidence on clinical utility and diagnostic yield of WES and WGS across non-oncology indications, with extensive focus on prenatal/obstetric uses, reanalysis, and rapid sequencing in critically ill infants; it informs coverage considerations for commercial and individual exchange populations. This excerpt (part 2 of 4) provides literature summaries for multiple indications and topics but does not include explicit enrollment criteria or billing instructions in this segment.

Policy Summary

PayerUnitedHealthcare

PolicyWhole Exome and Whole Genome Sequencing (Non-Oncology Conditions)

Policy CodePolicy N/A

Change Typeclarified / revised / removed

Effective DateJanuary 1, 2026

Next Review DateN/A

Key ActionDocument prior normal CMA/karyotype before considering prenatal ES/WGS and indicate whether trio testing was performed; follow recommended reanalysis intervals (at least every 18 months) and document reanalysis attempts and outcomes.

SourceLink

POLICY UPDATE CHANGES

Created shared policy version to support application to Oxford plan membership.

Updated list of applicable CPT codes to reflect annual edits; added 81354.

Archived previous policy versions 2025T0589Y and LABORATORY 024.24.

40%WGS diagnostic rate (Stranneheim et al.)

63.2%Prenatal ES skeletal incremental yield

32%Prenatal ES CNS incremental yield

Coverage Summary & Scope

Scope: This excerpt (part 2 of 4) reviews evidence on the diagnostic yield and clinical utility of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) across non-oncology conditions with extensive emphasis on prenatal/obstetric indications, reanalysis, and rapid sequencing in critically ill infants, and is intended to inform coverage considerations for commercial and individual exchange populations.

Overview: The document's coverage stance for this segment is informational; it summarizes literature, systematic reviews, cohort studies, and professional society guidance about WES/WGS performance, settings of use, and emerging technologies. This part does not contain explicit enrollment criteria, prior authorization rules, or billing instructions — those are found elsewhere in the full policy.

Key thresholds and quick facts

Reanalysis interval recommendationAt least 18 months

Increased nuchal translucency threshold>= 5 mm

Examples of pooled prenatal incremental yieldsSkeletal abnormalities ~60-63%; CNS anomalies ~32%; CAKUT ~26%; ACC ~43%; CHD overall ~17%

Rapid sequencing pooled diagnostic yield (critically ill infants)~42% (rWES ~50%, rWGS ~37%; urWGS higher in some trials)

Reanalysis added-diagnoses examplesMedian reanalysis yield ~15%; Tan cohort added diagnoses 17% when combined with additional methods

Billing/enrollment criteria in this excerptNot included in this segment (absent) — refer to member-specific benefit plan and other policy sections

Medical-Necessity / Coverage Stances (criteria trees)

Rapid Sequencing (rWES/rWGS/urWGS) coverage stance

Covered/Not supported statements based on setting:

ALL of the following

rWES, rWGS, and urWGS have demonstrated clinical utility in critically ill infants in the inpatient setting (evidence supports use).
Supported by pooled diagnostic yields and trials in critically ill hospitalized infants.
Use of rWES, rWGS, and urWGS in the outpatient setting is not supported due to lack of evidence.
Policy states outpatient use is unproven and not medically necessary.

Reanalysis of Exome Sequencing Data

Recommendations from evidence:

ALL of the following

Provider Actions, Documentation & Billing Notes

Documentation / Clinical Requirements

Billing / Authorization Considerations

Applicable Codes & Archived Identifiers

Note

Background & Evidence Summary

This policy section summarizes peer-reviewed studies and systematic reviews on WES and WGS diagnostic yield and clinical utility across a range of non-oncology conditions, with emphasis on prenatal indications (skeletal abnormalities, CNS anomalies, CHD, CAKUT, ACC, pregnancy loss).

The literature is heterogeneous: many studies are nonrandomized or lack comparison groups, vary by sequencing platform and coverage, and differ in trio versus proband-only strategies. Several meta-analyses and cohort studies report substantial incremental prenatal ES yields by phenotype (examples: skeletal abnormalities ~60-63%, CNS anomalies ~32%, CHD overall ~17.4%, CAKUT ~26%, ACC pooled ~43%).

Reanalysis of ES/WGS data increases diagnostic yield (reported incremental gains across studies and cohorts ranging from small percentages up to ~20%, with recommendations for periodic reanalysis at at least 18 months and use of additional methods such as trio testing, CNV detection, or repeat sequencing).

Rapid sequencing (rWES/rWGS/urWGS) shows pooled diagnostic yield in critically ill infants (~42% pooled; rWES ~50%, rWGS ~37%; urWGS higher in some trials), but evidence for outpatient rapid sequencing is limited and not supported for outpatient use.

Study/Source	Key finding
Stranneheim et al. (2021)	WGS achieved a molecular diagnosis in 40% of 4437 individuals with diagnoses across disease groups (19–54%) and enabled >1200 rare disease diagnoses.
Xiao et al. (2022)	Systematic review/meta-analysis of 23 studies (1567 critically ill infants) found pooled diagnostic yield for rapid sequencing ~42% (rWES 50%, rWGS 37%), supporting use in critically ill inpatient infants.
Kingsmore et al. (2019) NSIGHT2	Randomized trial in critically ill infants: rWES and rWGS diagnostic yields ~19–20%; urWGS had higher diagnostic rate (46%) and faster turnaround; supports rapid sequencing in hospitalized critically ill infants.
Tan et al. (2020)	Reanalysis study: two-point reanalysis alone yielded no new diagnoses in cohort, but incorporating additional methods (repeat sequencing, trio testing, CNV detection) produced 10 new diagnoses (17%); recommended reanalysis interval ≥18 months.
Reanalysis studies (e.g., URD‑Cat Bullich 2022, Vorsteveld 2024, Schobers 2022)	Systematic reanalysis increases diagnostic yield (examples: URD‑Cat ~20.7% new diagnoses; Vorsteveld systematic reanalysis raised yield from 11.8% to 15.2%); many new diagnoses due to new gene‑disease associations and improved analytics.
Kerkhof et al. (2024) episignature testing	Retrospective series (n=2399) reported diagnostic yields of 18.7% for comprehensive episignature analysis and 32.4% for targeted analyses, but noted limitations (restricted to conditions with known biomarkers, potential overlapping episignatures).
Lee et al. (2020) RNAseq integration	In a specialized referral cohort (WES/WGS with RNAseq), integration of RNAseq identified 7 additional diagnoses (15%) among probands with prior negative genome analyses, but limitations include tissue‑specific expression and specialized setting.

Definitions

Trio sequencing: Sequencing of the proband and both biological parents to aid variant interpretation and determine inheritance; many studies report higher diagnostic yield with trio approaches and professional guidance recommends parental samples when feasible.

Incremental diagnostic yield: The additional proportion of cases with pathogenic or likely pathogenic variants identified by ES/WGS beyond standard testing (karyotype/CMA); meta-analyses report pooled incremental yields that vary by phenotype (examples: pooled prenatal incremental yields range from low single digits to >60% depending on phenotype).

rWES: Rapid whole exome sequencing with accelerated turnaround intended for critically ill patients; evidence supports use in hospitalized critically ill infants but not outpatient settings.

rWGS/urWGS: Rapid or ultra-rapid whole genome sequencing with very short turnaround times, used primarily in critical inpatient settings; urWGS may yield faster results and higher diagnostic rates in some studies.

OGM: Optical Genome Mapping, a technology for detecting structural chromosomal abnormalities; proof-of-principle studies show concordance with standard assays but clinical utility evidence is insufficient.

Episignature testing: Clinical DNA methylation profile (epigenetic) analysis to detect disease-specific methylation 'episignatures'; retrospective series report diagnostic yields (e.g., ~18.7% comprehensive, ~32.4% targeted) but routine clinical utility is not established.

Revision History

01/01/2026material_revisionLatest

Applicable Codes updated in policy history dated 01/01/2026: Updated list of applicable CPT codes to reflect annual edits; added 81354.

01/01/2026template_updateLatest

Template update to create a shared policy version applicable to Oxford membership: Created shared policy version to support application to Oxford plan membership.

01/01/2026archival_note

Professional Society Guidance Summaries

Coverage stance:

ref":"b1_3","title":"Optical Genome Mapping (OGM)"},{

citations":["68","68","68"],"intro":"Coverage stance:","nodes":["{\"operator\":\"all\",\"n\":0,\"label\":\"\",\"text\":\"Insufficient evidence to support routine use of epigenetic signature analysis in diagnosis/management of constitutional disorders; not supported presently.\",\"threshold\":\"\",\"note\":\"Policy states episignature testing is unproven and not medically necessary for routine use.\",\"children\":[]}","{\"operator\":\"all\",\"n\":0,\"label\":\"Diagnostic yield studies and limitations\",\"text\":\"Large retrospective series reported diagnostic yields (18.7% for comprehensive analysis; 32.4% for targeted analysis) but limitations include restriction to conditions with known biomarkers and potential false positives from overlapping episignatures.\",\"threshold\":\"\",\"note\":\"Kerkhof et al. reported yields and noted limitations including biomarker restriction and potential false positives.\",\"children\":[]}"] ,"ref":"b1_4","title":"Epigenetic Signature Analysis (Episignature)"},{

citations":["72","70","71","82","79","83","77","81"],"intro":"Key recommendations from cited organizations:","nodes":["{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"ACMG: WES/WGS recommended as first- or second-tier testing for congenital anomalies or DD/ID with onset in childhood; testing selection should be phenotype-driven; consider trio testing when feasible; reanalysis recommended when nondiagnostic.\",\"threshold\":\"\",\"note\":\"ACMG guidance and practice resources endorse WES/WGS in these contexts and recommend reanalysis and phenotype-driven test selection.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"AAP: Recommends CMA as first-tier for GDD/ID along with WES (sequential or concurrent); WES/WGS may be reanalyzed every 1-2 years if negative; genome-wide methylation testing limited utility primarily for VUS evaluation.\",\"threshold\":\"\",\"note\":\"AAP clinical report recommends CMA and WES and periodic reanalysis; notes limited role for methylation testing.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"AAN/AANEM: Low level evidence supports WES/WGS in selected congenital muscular dystrophy cases after routine testing fails to identify variant; genetic testing critical for neuromuscular disorders though no specific methodology endorsed.\",\"threshold\":\"\",\"note\":\"AAN/AANEM statements note consideration of WES/WGS and importance of genetic testing in neuromuscular disease.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"ACOG: Routine WES/WGS for prenatal diagnosis not recommended outside trials; WES may be reasonable in certain prenatal contexts when standard testing is negative.\",\"threshold\":\"\",\"note\":\"ACOG committee opinions and assessments advise against routine prenatal WES/WGS outside trials but allow consideration when standard testing is negative.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"ESH G: Recommend introducing WGS in diagnostics when it improves quality/diagnostic yield; testing should be in accredited labs with validation; confirm research results in diagnostic labs.\",\"threshold\":\"\",\"note\":\"ESHG recommendations support WGS introduction when beneficial and emphasize laboratory accreditation and validation.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"ILAE: WES/WGS (including CNV analysis) recommended as first-line testing for many genetic epilepsies; periodic genetic reevaluation and reanalysis recommended.\",\"threshold\":\"\",\"note\":\"ILAE guidance recommends WES/WGS first-line in many epilepsy contexts and periodic reevaluation.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"NSGC: Strongly recommends WES/WGS or multi-gene panel (>25 genes) as first-tier for unexplained epilepsy regardless of age; WES/WGS conditionally recommended over panels; testing should be ordered/interpreted by qualified provider with counseling.\",\"threshold\":\"\",\"note\":\"NSGC guideline supports WES/WGS or large panels as first-tier and emphasizes provider qualifications and counseling.\",\"children\":[]}","{\"operator\":\"any\",\"n\":0,\"label\":\"\",\"text\":\"ASHG: Genetic testing should be limited to targeted panels when appropriate; WES/WGS appropriate when prior limited testing fails; not indicated for screening healthy children.\",\"threshold\":\"\",\"note\":\"ASHG policy recommends targeted testing when suitable and reserves WES/WGS for unresolved cases, not screening.\",\"children\":[]}"] }